4 results
Objectives:Primary:• To determine the absolute bioavailability of niraparib by using an intravenous (IV) niraparibmicrodose of 100 µg (containing approximately 1 µCi of [14C]-niraparib) in subjects with cancer.Secondary:• To characterize the…
To evaluate the safety and tolerability of XXB750 in adult participants with chronic stable HFrEF/HFmrEF.
Primary:• Progression-free survival (PFS) of unesbulin plus dacarbazine (DTIC) versus placebo plus DTICSecondary:Efficacy:• Overall survival (OS) of subjects treated with unesbulin plus DTIC versus placebo plus DTIC• Antitumor activity of unesbulin…
To evaluate the efficacy and dose-response relationship of XXB750 30 mg SC q4w, 60 mg SC q4w, 120 mg SC q4w, and 240 mg SC q4w compared to placebo in reducing the mean 24hr ambulatory systolic blood pressure (mean 24hr SBP) from baseline to Week 12.…